Estimates Revisions TScan Therapeutics, Inc.
Stocks
TCRX
US89854M1018
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 05/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.3915 USD | +5.55% |
|
-48.04% | -60.85% |
| 09-02 | Needham Downgrades TScan Therapeutics to Hold From Buy | MT |
| 09-02 | Wedbush Downgrades TScan Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $5 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- TCRX Stock
- Consensus TScan Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
